Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Myasthenia Gravis
Biotech
Kyverna links CAR-T to autoimmune improvements in small trial
Kyverna saw deep, sustained improvements in autoimmune disease patients who received a single dose of its CAR T-cell therapy KYV-101.
Nick Paul Taylor
Oct 29, 2025 10:00am
Dianthus' gMG asset blooms as phase 2 win sets up pivotal plans
Sep 8, 2025 9:24am
Regeneron posts phase 3 win, advancing push to muscle in on gMG
Aug 26, 2025 9:41am
AstraZeneca's blockbuster contender hits phase 3 gMG goals
Jul 24, 2025 6:20am
Fierce Pharma
Vor Bio's surprise $4B revival deal splits investor reactions
Jun 26, 2025 10:55am
J&J links FcRn blocker to sustained benefits as FDA ruling nears
Apr 8, 2025 10:21am